Scientists have developed an ultra-sensitive graphene foam biosensor that detects tau protein at femtomolar levels, offering a promising tool for early Alzheimer's diagnosis and clinical use.
Image Credit: FabrikaSimf/Shutterstock.com
Alzheimer's disease is a progressive brain disorder defined by memory loss and cognitive decline. It is caused, in part, by the buildup of abnormal proteins. Tau protein is a critical biomarker among these that helps in the early detection of the disease, particularly the tau-441 isoform.
However, current diagnostic techniques such as cerebrospinal fluid analysis and advanced imaging are invasive, expensive, and difficult to implement outside specialist settings. These limits have prompted researchers to look for more reliable tools that are less invasive and lower in cost by making them able to detect tau in more accessible fluids like blood or serum.
Graphene Foam: Possibilities
Graphene, a single layer of carbon atoms arranged in a honeycomb pattern, is known for its excellent conductivity and strength. But, graphene's conductivity can be compromised when its carbon lattice is oxidized to introduce functional groups for biomolecule immobilization.
Three-dimensional graphene foam is garnering interest as it provides a much larger surface area for detecting biomolecules and allows better electron transfer, both vital for biosensor performance.
In a recent Biosensors study, researchers have used a version of graphene foam modified with carboxyl (COOH) groups, which allows antibodies to attach securely via carbodiimide chemistry. The strong amide bond formed between the sensor and the tau-441 bodies enables precise, specific protein detection.
Building the Sensor
The sensor was built using commercially available COOH-functionalised graphene foam electrodes. The team first examined the foam's surface structure to confirm that carboxyl groups were present and did not disrupt the foam's porous architecture. Using EDC-NHS reagents, they activated the surface and immobilised antibodies specific to tau-441.
They then optimised various steps, including reagent concentration and incubation times, to ensure strong antibody binding without affecting the material's electrical performance. Electrochemical techniques such as cyclic voltammetry and differential pulse voltammetry were used to measure current changes when tau-441 protein was introduced.
As tau-441 bound to the antibodies, it reduced the flow of electrons, an effect recorded as a drop in current. These changes were used to quantify the amount of protein present.
Results Show High Sensitivity and Specificity
Tests showed the sensor could detect tau-441 in concentrations ranging from one femtomolar to 10 nanomolar, with a limit of detection of just 0.14 femtomolar. This level of sensitivity is significantly higher than that of many existing biosensors.
Importantly, the sensor also showed strong specificity. It successfully distinguished tau-441, showing minimal response to other Alzheimer's-related proteins, including tau-217, tau-181, and amyloid-beta (Aβ1-40 and Aβ1-42), as well as common serum proteins like BSA. This specificity reduces the likelihood of false positives.
Trials using human serum samples demonstrated that the sensor performed well even in complex biological fluids. Using scanning electron microscopy, the team also confirmed that the antibody coating was distributed evenly across the foam surface, supporting consistent performance across tests.
Download your PDF copy now!
A Step Toward Practical Diagnostics
One of the key strengths of this sensor lies in its non-covalent approach to functionalization. With π-π stacking between the graphene surface and the carboxyl modifiers, functionalizing the foam in this way avoids disrupting the carbon lattice and maintains high conductivity. Combined with the foam's large surface area, this results in a high-density, high-performance biosensing platform.
The sensor's simplicity, low cost, and stability in real-world samples make it well-suited for future clinical use, including portable or point-of-care diagnostics.
While further work is needed to refine the manufacturing process and ensure long-term stability, this study represents a significant advance in the development of sensitive, non-invasive tools for Alzheimer's diagnosis. The flexible design also opens the door to multiplexed sensors capable of detecting multiple biomarkers simultaneously.
Journal Reference
Nazir S., et al. (2025). Electrochemical Immunosensor Using COOH-Functionalized 3D Graphene Electrodes for Sensitive Detection of Tau-441 Protein. Biosensors 15(7):465. DOI: 10.3390/bios15070465, https://www.mdpi.com/2079-6374/15/7/465.